Try our beta test site

Special Investigation in Patients With Rheumatoid Arthritis (Combo Study; Adalimumab With High Dose Methotrexate)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) ) Identifier:
First received: November 27, 2012
Last updated: January 31, 2017
Last verified: January 2017
In the usual clinical setting, patients with Rheumatoid Arthritis who receive adalimumab (Humira®) and high-dose Methotrexate (≥12 mg/week) will be investigated prospectively for effectiveness according to Disease Activity Score 28, modified Total Sharp Score, and other measures, as well as safety in terms of the incidence and pattern of occurrence of adverse drug reactions.

Rheumatoid Arthritis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Special Investigation in Patients With Rheumatoid Arthritis (Combo Study : Adalimumab With High Dose MTX)

Resource links provided by NLM:

Further study details as provided by AbbVie:

Primary Outcome Measures:
  • Disease activity Score 28 [ Time Frame: at week 12 ]
  • Disease activity Score 28 [ Time Frame: at week 24 ]
  • Disease activity Score 28 [ Time Frame: at week 52 ]

Secondary Outcome Measures:
  • Clinical disease activity index [ Time Frame: at week 12 ]
  • Clinical disease activity index [ Time Frame: at week 24 ]
  • Clinical disease activity index [ Time Frame: at week 52 ]
  • Simplified disease activity index [ Time Frame: at week 12 ]
  • Simplified disease activity index [ Time Frame: at week 24 ]
  • Simplified disease activity index [ Time Frame: at week 52 ]
  • X-ray findings for hands and feet [ Time Frame: at week 52 ]
  • Health Assessment Questionnaire [ Time Frame: at week 12 ]
  • Health Assessment Questionnaire [ Time Frame: at week 24 ]
  • Health Assessment Questionnaire [ Time Frame: at week 52 ]
  • Number of patients with adverse events [ Time Frame: at week 52 ]
    Occurrence of adverse event (yes or no), nature of adverse events, date of onset, seriousness,clinical course of adverse events, outcome, measures, causal relationship between the event and Humira

Estimated Enrollment: 350
Study Start Date: September 2012
Estimated Study Completion Date: March 2017
Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)
those with an exposure


Ages Eligible for Study:   16 Years to 99 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Single-arm, Multi-center, Prospective Cohort

Inclusion Criteria:

The subjects of this study are RA patients and to whom adalimumab is administered. They should be satisfying the following conditions:

  • Disease duration of RA ≤2 years
  • MTX administration ≥3 months
  • Dose of MTX ≥12mg/week
  • DAS28-CRP >3.2

Exclusion Criteria:

  • Patients who have been previously treated with biologics (including TNF inhibitors others)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01736189

  Show 144 Study Locations
Sponsors and Collaborators
AbbVie (prior sponsor, Abbott)
Study Director: Sarina Kurimoto, MD Abbvie GK
  More Information

Additional Information:
Responsible Party: AbbVie (prior sponsor, Abbott) Identifier: NCT01736189     History of Changes
Other Study ID Numbers: P13-684 
Study First Received: November 27, 2012
Last Updated: January 31, 2017

Keywords provided by AbbVie:
Rheumatoid arthritis

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Anti-Inflammatory Agents
Antirheumatic Agents processed this record on February 24, 2017